Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

Mattía Galli(Maria Cecilia Hospital), Dominick J. Angiolillo(University of Florida), Domenico D’Amario(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Italo Porto(University of Genoa), Stefano Benenati(Ospedale Policlinico San Martino), Francesco Franchi(Florida College), Davide Capodanno(University of Catania), Fabiana Rollini(Florida College)
The Lancet
April 1, 2021
10.1016/s0140-6736(21)00533-x
Cited by 229

Related Papers

2024 ESC Guidelines for the management of chronic coronary syndromes
|European Heart Journal|2024|2.3k
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|877
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Platelet Inhibition with Cangrelor in Patients Undergoing PCI
|New England Journal of Medicine|2009|618